Ruxolitinib
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasm (MPN)
Conditions
Myeloproliferative Neoplasm (MPN)
Trial Timeline
Aug 20, 2008 → Aug 20, 2018
NCT ID
NCT00726232About Ruxolitinib
Ruxolitinib is a phase 2 stage product being developed by Incyte for Myeloproliferative Neoplasm (MPN). The current trial status is terminated. This product is registered under clinical trial identifier NCT00726232. Target conditions include Myeloproliferative Neoplasm (MPN).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03147742 | Pre-clinical | Completed |
| NCT04355793 | Pre-clinical | Completed |
| NCT01730755 | Pre-clinical | Completed |
| NCT05722912 | Pre-clinical | Completed |
| NCT07424222 | Phase 1 | Recruiting |
| NCT07356245 | Phase 2 | Recruiting |
| NCT07252050 | Phase 1/2 | Recruiting |
| NCT07085039 | Phase 2 | Recruiting |
| NCT05293717 | Phase 1/2 | Completed |
| NCT04908280 | Phase 2 | Completed |
| NCT04807777 | Phase 2 | Terminated |
| NCT04644211 | Phase 2 | Recruiting |
| NCT04354714 | Phase 2 | Withdrawn |
| NCT03801434 | Phase 2 | Recruiting |
| NCT03722407 | Phase 2 | Active |
| NCT03674047 | Phase 2 | Active |
| NCT03427866 | Phase 2 | Completed |
| NCT03153982 | Phase 2 | Terminated |
| NCT01895842 | Phase 1 | Completed |
| NCT01776723 | Phase 1/2 | Completed |
Competing Products
20 competing products in Myeloproliferative Neoplasm (MPN)